Abbott Hospital Products International Expansion Key To Future Growth
This article was originally published in The Gray Sheet
Executive Summary
Abbott is predicting low-to-mid single-digit growth of its $2.5 bil. Global Hospital Products spin-off after its divestiture to shareholders in the first half of 2004
You may also be interested in...
Abbott Sharpens Focus On Higher-Margin Products, Spins Off Hospital Unit
Abbott will refocus resources on advanced technologies including stents and spinal fusion systems after divesting the lion's share of its slower-growth hospital products unit in a spin-off to shareholders
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.